BV plus chemotherapy prior to transplant highly effective in RRHL
HL patients who are refractory or relapse after upfront chemotherapy receive salvage therapy followed by autologous stem cell transplantation as standard of care. Dr. Ramón García-Sanz (University Hospital of Salamanca, Spain) presented the first results of the phase I-II BRESHAP study evaluating the addition of brentuximab vedotin (BV) to the standard salvage regimen (ESHAP) in refractory/relapsed (RR) HL patients. Almost all patients (95%) responded to the BRESHAP protocol, with 71% metabolic complete responses. After 30 months PFS was 71% and OS was 91%. “Brentuximab vedotin can be safely combined with ESHAP in RRHL patients who are candidates for autologous transplantation. BRESHAP is an excellent mobilization regimen for autologous peripheral blood stem cell collection”, concluded Garcia-Sanz.